

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (HARMONi-7)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- may be restricted in physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - diagnosis of metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) - have not received any treatment - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- small cell lung cancer - known genetic alterations that have treatment options - have received treatment for this cancer - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Non-Small Cell Lung Cancer, NSCLC

More Information

Description: The purpose of this research is to measure the safety and effectiveness of ivonescimab compared to pembrolizumab. Ivonescimab is an antibody designed to block proteins that help cancer cells grow and spread, and by blocking these proteins may potentially slow cancer progression. Participants will have a 50% chance of being assigned to either the ivonescimab treatment group or the pembrolizumab treatment group.

Study Contact: Faysal Haroun - fharoun10@umphysicians.umn.edu

Principal Investigator: Faysal Haroun

Phase: PHASE3

IRB Number: STUDY00025046

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.